# NGL Fine Chem share price today (NGL Fine Chem Ltd, NSE: NGLFINE) > NGL Fine Chem share price today: ₹2,747.60 at the NSE close on 20 November 2026, up 105.8% in a year. NGL Fine Chem (NSE: NGLFINE) is worth ₹1,699 crore, trades at a P/E of 26.6 and has closed between ₹1,279.35 and ₹3,462.60 over the past 52 weeks. > NGL Fine Chem Ltd's earnings have grown faster than its share price. Earnings per share grew +127.9% in a year while the price moved +105.8%. NGLFINE · Pharma - Animal · data as of 20 November 2026. Page: https://www.sectoralpha.in/stocks/ngl-fine-chem-ltd Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms ## Key numbers - Business trend: Turning around, from the last 12 quarters - Price: ₹2,747.60 (+105.8% in a year) - P/E: 26.6× (lower than 64% of the last 11 years) - Revenue (Sep 2026): ₹159 Cr (+32.5% on a year ago) - Profit (Sep 2026): ₹16.0 Cr (+60.0% on a year ago) - Operating margin: 17.6% (+3.4 points on a year ago) - ROCE: 19%, FY26 - ROIC: 13.1%, against a 12.0% cost of capital: +1.1 points Biggest thing to watch: the price has already been rising for 41 weeks, so timing is the risk more than the business. ## What is the NGL Fine Chem share price today? NGL Fine Chem Ltd's share price was ₹2,747.60 at the close on 20 November 2026. It has been rising for 41 weeks. That is 5.5% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1,279 and ₹3,463, and at that close it sat 67% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 1 week running. Over the last 11 years the share price moved +1,347% while the NIFTY 500 moved +306%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 13 November 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at NGL Fine Chem this quarter? Three changes stood out: revenue up on a year earlier for 6 quarters in a row, highest quarterly revenue in 16 quarters and profit up on a year earlier for 4 quarters in a row. 1. Revenue up on a year earlier for 6 quarters in a row In the September 2026 quarter revenue was ₹159 crore, +32.5% on a year earlier. Why: Sales rose because the company sold more animal health ingredients, helped slightly by a weaker rupee. It did not get a broad price rise across its products. Next results: check how much of the new Tarapur plant is actually used and whether that turns into sales, because management expects about 30 to 40 percent use over the next two to three quarters. From the earnings call on 12 Nov 2026. 2. Highest quarterly revenue in 16 quarters Revenue of ₹159 crore in the September 2026 quarter is the highest of the last 16 quarters. Why: The quarter was the best in 16 quarters because the company sold more animal health ingredients, with only a slight help from a weaker rupee and no broad price rise. From the earnings call on 12 Nov 2026. 3. Profit up on a year earlier for 4 quarters in a row In the September 2026 quarter profit was ₹16 crore, +60% on a year earlier. Why: Profit rose because gross margin, the profit left after direct product costs, improved. Some earlier cost rises were passed on and fixed costs were spread over more sales. Next results: check whether operating profit margin, what is left after running costs, stays in the 15 to 18 percent range while new plant costs and hiring rise. From the earnings call on 12 Nov 2026. ## What are NGL Fine Chem's latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), NGL Fine Chem reported revenue of ₹159 crore, up 32.5% from ₹120 crore a year earlier, and a profit of ₹16.0 crore, up 60.0% from ₹10.0 crore. ### NGL Fine Chem results: July to September 2026 against a year earlier | Measure | July to September 2026 | July to September 2025 | Change | | --- | --- | --- | --- | | Revenue | ₹159 crore | ₹120 crore | +32.5% | | Profit | ₹16.0 crore | ₹10.0 crore | +60.0% | | Earnings per share | ₹26.30 | ₹15.59 | +68.7% | | Operating margin | 17.6% | 14.2% | +3.4 points | The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). NGL Fine Chem's management discussed these results on a call held on 12 November 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.) ## What is the NGL Fine Chem share price history? NGL Fine Chem closed at ₹2,747.60 on 20 November 2026, up 105.8% from ₹1,335.40 a year earlier (21 November 2025) and down 3.2% over five years. Its highest weekly close since February 2016 was ₹3,488.80 on 6 August 2021. ### NGL Fine Chem share price: then and now | When | Close | Change to 20 Nov 2026 | | --- | --- | --- | | 1 week ago · 13 Nov 2026 | ₹3,041.30 | −9.7% | | 1 month ago · 19 Oct 2026 | ₹2,772.90 | −0.9% | | 6 months ago · 22 May 2026 | ₹2,770.10 | −0.8% | | 1 year ago · 21 Nov 2025 | ₹1,335.40 | +105.8% | | 3 years ago · 17 Nov 2023 | ₹1,971.20 | +39.4% | | 5 years ago · 18 Nov 2021 | ₹2,839.20 | −3.2% | | 10 years ago · 18 Nov 2016 | ₹268.00 | +925.2% | | Earliest and lowest weekly close in our records · 26 Feb 2016 | ₹189.90 | +1,346.9% | | Highest weekly close since February 2016 · 6 Aug 2021 | ₹3,488.80 | −21.2% | | 52-week high (weekly close) · 14 Aug 2026 | ₹3,462.60 | −20.6% | | 52-week low (weekly close) · 19 Dec 2025 | ₹1,279.35 | +114.8% | Weekly closing prices. Each change is the move from that price to the 20 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (568 weekly closes from 26 February 2016 to 20 November 2026.) ## What is the latest news on NGL Fine Chem? 20 Nov 2026: NGL Fine Chem closed at ₹2,747.60, down 9.7% on the week and down 0.9% on the month. 12 Nov 2026: NGL Fine Chem held its results call for July to September 2026. Management guided: Phase II utilization 30-40% over next 2-3 quarters with room for both regulated and existing demand for next 3 years. ### Earlier - Results for July to September 2026: Revenue up 32.5% and profit up 60.0% on a year earlier. - 18 Aug 2026: ex-date for a dividend of ₹1.75 a share. ## What dividend does NGL Fine Chem pay? NGL Fine Chem paid ₹1.75 a share in regular dividends in the 12 months to 20 November 2026 (1 payment), a yield of 0.06% at the ₹2,747.60 close on 20 November 2026. The last was a dividend of ₹1.75 a share, ex-date 18 August 2026. ### NGL Fine Chem dividends since 1 April 2021 | Ex-date | Dividend per share | Type | | --- | --- | --- | | 18 Aug 2026 | ₹1.75 | Dividend | | 12 Aug 2025 | ₹1.75 | Dividend | | 16 Aug 2024 | ₹1.75 | Dividend | | 18 Aug 2023 | ₹1.75 | Dividend | Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here. 3 of 5 Of the last 5 financial years, years with an NSE dividend record Yes. NGL Fine Chem Ltd paid out 2% of its profit as dividends in FY26, and it paid a dividend in 8 of its last 13 reported years. (From the NSE corporate-actions record, read 20 November 2026.) ## What did NGL Fine Chem management say on the latest results call? On the call for July to September 2026, held on 12 November 2026, NGL Fine Chem's management guided: Phase II utilization 30-40% over next 2-3 quarters with room for both regulated and existing demand for next 3 years. > “Our focus now is on converting the investment in capacity and working capital into sales, operating cash flow, and improved results.” > Rahul Nachane, on the call for July to September 2026 ### What management guided - Long-term gross 50-55% and operating profit 15-18% with regulated 18-22% premium. - Phase II cost build capped with finance up not more than 20% and depreciation up not more than ₹3 crore over H1 plus balance hiring. - EU transfer program plus remaining EU submissions planned by end-CY2027 and US customer submission by December 2026. - Regulated critical mass expected 2028-2030 while ₹50-60 crore current-year Europe goal likely missed modestly. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijoristack.ai/concall/transcript/2778-12-Nov-2026.pdf). (From the call for July to September 2026, 12 November 2026.) ## What to watch in NGL Fine Chem's next results? When NGL Fine Chem reports October to December 2026, these are the 2 checks that show whether the story is still on course. First: Phase II utilization reaching flagged ramp band on existing-market volumes - check production ramp and sales conversion progress. Management raised each of these on the latest results call. - Phase II utilization reaching flagged ramp band on existing-market volumes - check production ramp and sales conversion progress. - United States customer submission completing by flagged deadline to start audit clock - check filing progress and inspection scheduling. ## Which stock lists is NGL Fine Chem on? NGL Fine Chem is on one of our India lists: Pharma stocks. [Pharma stocks Market value: ₹1,717 crore](https://www.sectoralpha.in/sectors/pharma-stocks-india) ## Is NGL Fine Chem profitable? NGL Fine Chem Ltd earned ₹16.0 Cr of net profit in the Sep 2026 quarter, +60.0% on the same quarter a year earlier. That is the 4th quarter in a row of profit growth. Full-year FY26 profit was ₹48.0 Cr. Over 10 years profit has grown 15.9% a year on average. The same quarter a year earlier earned ₹10.0 Cr. The Sep 2026 quarter's profit is 10.1% of that quarter's revenue. For the full year, FY26 profit was ₹48.0 Cr (+128.6% on the year before). Why profit moved: revenue changed +32.5% on a year earlier and the margin moved +3.4 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +715.0% and revenue +41.7%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does NGL Fine Chem make, and is it growing? NGL Fine Chem Ltd reported ₹159 Cr of revenue in the Sep 2026 quarter, +32.5% on the same quarter a year earlier. That is the 6th quarter in a row with growth on the year before. Over 10 years it has grown 18.0% a year on average. The last full year, FY26, came in at ₹501 Cr. Why this happened. Phase 1 is operational at 70-80% utilization. Phase 2 construction delayed from Q1 FY27 to early Q2 FY27 due to localized gas shortage and labor constraints; H2 FY27 commercial production goal maintained. This is the third commissioning timeline slip. Peak revenue potential from Phase 2 guided at ₹350-400 Cr, management explicitly revised upward from the prior ₹250-300 Cr (May 2025 call) but attributed the revision incorrectly (a documented inconsistency). Post-Phase 2 completion, annual capex guided at ₹15-20 Cr. Ramp to peak utilization… The last four reported quarters add to ₹575 Cr. FY26 revenue was ₹501 Cr, +36.1% on the year before. Recent pace: the last four quarters grew +41.7% on average, against 18.0% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +40.9%, against +24.3% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +200.0%, against +24.0% a year (accelerating). ## How much of every ₹100 of sales does NGL Fine Chem keep? NGL Fine Chem Ltd's operating margin was 17.6% in the Sep 2026 quarter, 3.4 percentage points higher than the same quarter a year ago. Across 13 years it has been between 9.5% and 31.0%. The latest quarter is within that range. Why this happened. The FY26 full-year delivery confirms what three quarters of recovery had suggested: the OPM collapse (FY25 annual 9.2%) has structurally reversed. Annual OPM reached 14.5% in FY26, up from 9.2% in FY25, with Q3 FY26 peaking at 18%. Q4 FY26 (Mar 2026) shows 14% OPM, sequential dip from 18% due to forex mark-to-market provisions on receivables and fixed-price RM contract inflation from geopolitical pressures (attributed explicitly in May 2026 call). Management secured partial price pass-through in Q1 FY27 and expects Q2 FY27 to show a stronger profile. Revenue growth was broad-based across geographies: 47 new customers added in Q4 FY26 alone, including Latin America as an emerging success… Why the margin moved: operating margin changed +3.4 percentage points on the year while gross margin changed +3.9 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is NGL Fine Chem's profit turning into cash? Over the last 3 years, 86% of NGL Fine Chem Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹43.0 Cr of operating cash against ₹48.0 Cr of profit. After ₹90.0 Cr of spending on assets, free cash was −₹47.0 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 86% of profit came in as cash: the cash cycle got 22 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: the bigger use of cash is spending on new assets, at 4.4× depreciation over three years. The next section checks what that spending is building. ## Where does NGL Fine Chem's cash go? NGL Fine Chem Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 104 days in FY26, up from 82 days in FY21. It spent ₹193 Cr on assets over the last 3 years. Customers take 95 days to pay, and stock sits for 106 days on average. At FY26 sales of ₹501 Cr, each day of that cycle ties up about ₹1.4 Cr, so roughly ₹143 Cr is tied up in the business at any time. FY26: customers took 95 days to pay and stock sat for 106 days, about 3.5 months of sales sitting as stock, for a full cycle of 104 days, longer than FY21's 82. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 106 days. Customers pay about 95 days after that. Suppliers are paid at 97 days. Together that makes the 104-day cycle. Spending on assets: ₹193 Cr over the last 3 years, against ₹44.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹95.0 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is NGL Fine Chem's P/E ratio, and how does it compare with its own history? NGL Fine Chem Ltd's P/E is 26.6×, in the middle of its own history: higher than 36% of past readings. Its usual P/E (the middle reading) is 30.6×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +127.9% while the price moved +105.8%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved −0.7% a year; about −0.2% a year came from earnings growth and about −0.5 percentage points from the multiple (roughly no change). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. ## What growth does the NGL Fine Chem share price assume? Worked out from its price on 27 August 2026, NGL Fine Chem Ltd's share price assumed profit growth of about 19.4% a year. Over the past 10 years its profit actually grew 15.9% a year. Today its P/E is 26.6×, lower than 64% of its own last 11 years. This is a one-day reading, taken on 27 August 2026. Every other number on this page, the multiple included, uses the latest price as of 20 November 2026. A higher price assumes more growth and a lower price less, so it changes whenever the price changes, and this page does not update it between measurements. ## Is the NGL Fine Chem business getting better or worse? NGL Fine Chem Ltd's business is turning around. Profit growth has swung from −48.8% at its recent low to +200.0%, improving for 4 quarters in a row, with ROCE rising at 23.0% (four quarters to Sep 2026). This is based on 12 quarters of 4 measures. Why it matters: a turn in growth is often where a bigger change starts. The lines say a turn is forming, so the question is whether the next quarters confirm it. ## What is the NGL Fine Chem story, and has it been checked? NGL Fine Chem Ltd's story is not scored yet against the checks our research set on 31 May 2026. Where it sits in its own cycle: expanding mid stage. Still open: May 2026 adds two new inconsistencies: EU revenue FY26 miss unacknowledged; Phase 2 peak revenue revised upward with incorrect prior-guidance attribution. Our read, 31 May 2026. From the numbers. QoQ momentum WEAKENING per prior snapshot. At 35.8x current vs 29x median and 43.7x prior peak, the… From the price. Price stage 2, week 41, above its 200-day line, relative strength falling. From the research. A veterinary API turnaround with confirmed FY26 delivery, four consecutive quarters of margin expansion, ₹48 Cr FY26 PAT (+127% YoY), with Phase 2 Tarapur commissioning imminent and US/EU regulatory ladders actively… What is not proven yet. May 2026 adds two new inconsistencies: EU revenue FY26 miss unacknowledged; Phase 2 peak revenue revised upward with incorrect prior-guidance attribution. The test written in advance. Management Credibility, Four Documented Inconsistencies. Measured by: Management Credibility, Four Documented Inconsistencies by the next result. The test written in advance. Raw Material Cost Reversal, OPM Fragility. Measured by: Raw Material Cost Reversal, OPM Fragility by the next result. The test written in advance. US FDA Audit Binary Outcome. Measured by: US FDA Audit Binary Outcome FY27/FY28 FDA audit announcement and outcome; 5 DMF filings progress + 6 additional goal by the next result. Lever 1 · Operating leverage: building. FY26 revenue ₹501 Cr (+36% YoY), PAT ₹48 Cr (+127% YoY), four consecutive OPM expansions confirm turnaround is multi-quarter and structurally driven. What proves it keeps working: Operating Leverage Inflection, FY26 Confirmed. It stops working if Q1 FY27 concall: explicit update on EU revenue quantum and Phase 2 commissioning status; whether FY26 EU miss is acknowledged. Lever 6 · Order-book wins: building. delayed to early Q2 FY27, H2 FY27 commercial production, peak revenue potential ₹350-400 Cr (revised from prior ₹250-300 Cr guidance). What proves it keeps working: Tarapur Phase 2 Commissioning. Lever 10 · New geographies: building. EU: 3 CEPs approved + 3 under review aiming for 6 by end-2026; EU revenue starting H2 FY27. US: 5 DMFs filed + 6 more planned; FDA audit FY27/FY28. What proves it keeps working: EU/US Regulated Market Ramp. Lever 3 · Management change: building. Portfolio doubled from 20 to 45 APIs in three years; annual new-product goal 9-10; Fluralaner and Afoxolaner (patent expiry ~2 years) in companion-animal pipeline. What proves it keeps working: Portfolio Expansion, 45 APIs from 20. Sources: our stock research file (31 May 2026) · quarterly results through Sep 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes. ## Did NGL Fine Chem management deliver what it promised? What NGL Fine Chem Ltd's management promised, against what actually happened: 4 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met. Tarapur Phase 2 Utilization Assumption Changed · 12 November 2026. In Nov 2025, management said the new plant would not have significant FY '27 utilization before U.S. FDA approval. In Nov 2026, management instead made existing-market demand the near-term ramp driver and forecast 30-40% utilization over the next 2-3 quarters, a material change to the expansion's utilization and margin assumptions. The latest call identifies current demand as the rationale but does not reconcile the revised forecast with the earlier FDA-dependent view. U.S. Regulatory Timeline Lost Its Prior Milestones · 12 November 2026. In Nov 2025, management gave a defined schedule of audits in the second quarter of the next financial year and commercial production in the latter half of FY '27. By Nov 2026, the customer filing was still expected only by December 2026 and the inspection and commercialization dates were open-ended. The latest dependency language acknowledges regulatory risk but does not reconcile the slippage from the earlier schedule. European Regulated-Market Ramp Delayed · 12 November 2026. In Nov 2025, management expected the relevant customer acquisitions in calendar year '27 or so. In Nov 2026, it said onboarding was slower than anticipated and placed critical mass between 2028 and 2030, materially delaying the regulated-market growth case. Management identified slower approvals and onboarding as the reason, but did not provide a revised revenue or recovery framework. European Market Materialization Delayed · 25 May 2026. However, in the May 2026 call, management completely contradicted this timeline, stating they anticipate European business to only begin coming in toward the second half of the current year (FY27), failing to address the previously guided FY26 sales. Every quote above is taken word for word from the company’s own earnings calls. ## What is NGL Fine Chem management's track record? Management does not correct the record - a recurring goalpost-moving pattern (the §3.3 said-vs-delivered-through-stress failure), though promoter conduct/capital structure is clean. Sources: - [nglfinechem.com](https://www.nglfinechem.com/disclosures-under-regulation.html) (Checked 15 June 2026.) ## How much does NGL Fine Chem earn on its capital? NGL Fine Chem Ltd earned a ROCE of 19% in FY26. That is up from a low of 10% in FY25. Its return on capital used (ROIC) is 1.1 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 9.6% net margin and 0.92× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 9.6% net margin × 0.92× asset turnover × 1.66× leverage (assets divided by equity) ≈ 14.7% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 13.1% − 12.0% = +1.1 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error. The 13.1% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 11.5%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does NGL Fine Chem have too much debt? NGL Fine Chem Ltd has total debt of ₹127 Cr against shareholder equity of ₹363 Cr as of Sep 2026, so its debt is 0.35× its equity. Year by year, that ratio went from 0.15 in FY22 to 0.37 in FY26. Keep that borrowing in mind when reading the returns on this page. ## What is the NGL Fine Chem shareholding pattern? No group of NGL Fine Chem Ltd's owners changed its stake by a full percentage point over the last two years. Foreign institutions moved +0.0 points over the same period, to 0.0%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Why this happened. Portfolio doubled from 20 to 45 APIs in three years; annual new-product goal 9-10; Fluralaner and Afoxolaner (patent expiry ~2 years) in companion-animal pipeline. Over the last two years: Promoters: −0.3 points over 8 quarters, to 72.5%; Foreign institutions: +0.0 points over 8 quarters, to 0.0%; Domestic institutions: +0.0 points over 8 quarters, to 0.0%. ## How far is NGL Fine Chem from balance-sheet trouble? For NGL Fine Chem Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does NGL Fine Chem rank in its industry? 77.6 out of 100, rank 1 of 3 in Pharma - Animal, with 87% of the evidence available. NGL Fine Chem Ltd scores 77.6 out of 100 against the 3 companies it is compared with in Pharma - Animal, ranking 1. Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. The four parts add up to the total exactly: 35 + 18.4 + 10.2 + 14 = 77.6. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is NGL Fine Chem compared with? NGL Fine Chem ranks 1 of 3 Pharma - Animal companies on the 4-Factor Sector Score, with 77.6 out of 100. 1. NGL Fine Chem Ltd this page NGLFINE · quiet · Most evidence points up · 87% evidence 77.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 35.0/35 · Revenue 40.9% · Profit 100% · Operating margin change 4 points · 100% evidence Capital efficiency 18.4/25 · ROCE 18.6% (year to Mar 2026) · Operating margin 17.6% · 100% evidence Valuation 10.2/20 · P/E 26.6× · PEG n/a · 35% evidence Relative strength 14.0/20 · Strength vs its industry (price vs its 52-week average, weekly) 12.3% · Strength vs NIFTY 500 (same reading) 20.7% · 1 year 105.8% · 100% evidence · 0 of 12 weeks ahead Exact sum: 35 + 18.4 + 10.2 + 14 = 77.6 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Hester Biosciences Ltd](https://www.sectoralpha.in/stocks/hester-biosciences-ltd) HESTERBIO · quiet · Most evidence points up · 64% evidence 74.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 33.2/35 · Revenue 17.3% · Profit 100% · Operating margin change 16 points · 95% evidence Capital efficiency 16.5/25 · ROCE 15.2% (year to Mar 2026) · Operating margin 33.7% · 76% evidence Valuation 12.2/20 · P/E 13.9× · PEG n/a · 35% evidence Relative strength 12.5/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 19.3% · 1 year 39.4% · 25% evidence · 4 of 12 weeks ahead Exact sum: 33.2 + 16.5 + 12.2 + 12.5 = 74.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Viyash Scientific Ltd](https://www.sectoralpha.in/stocks/viyash-scientific-ltd) VIYASH · quiet · Evidence leans up · 79% evidence 62.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.0/35 · Revenue 31.7% · Profit 72.2% · Operating margin change -3 points · 95% evidence Capital efficiency 12.3/25 · ROCE 13.4% (year to Mar 2026) · Operating margin 16.7% · 76% evidence Valuation 11.5/20 · P/E 44× · PEG n/a · 35% evidence Relative strength 12.9/20 · Strength vs its industry (price vs its 52-week average, weekly) -2.8% · Strength vs NIFTY 500 (same reading) 7.1% · 1 year -2.2% · 100% evidence · 0 of 12 weeks ahead Exact sum: 26 + 12.3 + 11.5 + 12.9 = 62.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Animal](https://www.sectoralpha.in/sectors/pharma-animal), all 3 compared on one page. ## Which companies are close to NGL Fine Chem in size? NGL Fine Chem is the 3rd largest of 3 Pharma - Animal companies on Sector Alpha by market value (at the 20 November 2026 close). Just above it: Viyash Scientific and Hester Biosciences. It is the smallest. ### Pharma - Animal companies close in size 1. [Viyash Scientific Ltd](https://www.sectoralpha.in/stocks/viyash-scientific-ltd) ₹10,314 crore 2. [Hester Biosciences Ltd](https://www.sectoralpha.in/stocks/hester-biosciences-ltd) ₹1,982 crore 3. NGL Fine Chem Ltd ₹1,698 crore [All 3 Pharma - Animal companies, largest first](https://www.sectoralpha.in/sectors/pharma-animal#all-companies) ### Companies close in size in other industries 1. [Skyways Air Services Ltd](https://www.sectoralpha.in/stocks/skyways-air-services-ltd) ₹1,700 crore 2. [Tinna Rubber & Infrastructure Ltd](https://www.sectoralpha.in/stocks/tinna-rubber-infrastructure-ltd) ₹1,700 crore · Rubber Processing/Rubber Products 3. NGL Fine Chem Ltd ₹1,698 crore 4. [HMA Agro Industries Ltd](https://www.sectoralpha.in/stocks/hma-agro-industries-ltd) ₹1,698 crore · FMCG - Animal/Polutry 5. [TIL Ltd](https://www.sectoralpha.in/stocks/til-ltd) ₹1,692 crore · Capital Goods - EPC/Cranes ## What else do people ask about NGL Fine Chem? ### What is NGL Fine Chem's share price today? NGL Fine Chem Ltd's share price is ₹2,747.60, +105.8% over the past year. The whole company is worth ₹1,699 Cr on the market. In the last 52 weeks it traded between ₹1,279 to ₹3,463; today it is 67% of the way up from the low, 5.5% above its 200-day average (as of 20 November 2026). ### What were NGL Fine Chem's latest quarterly results? NGL Fine Chem Ltd reported revenue of ₹159 Cr and net profit of ₹16.0 Cr for the Sep 2026 quarter. Revenue rose 32.5% and profit rose 60.0% compared with a year earlier. Earnings per share were ₹26.30. The operating margin was 17.6%, 3.4 percentage points higher than a year earlier (as of 20 November 2026). ### What is NGL Fine Chem's market cap? NGL Fine Chem Ltd's market capitalisation is ₹1,699 Cr at a share price of ₹2,747.60. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 20 November 2026). ### How is NGL Fine Chem performing? NGL Fine Chem Ltd's share price has been rising for 41 weeks. In its latest quarter, revenue rose 32.5% and profit rose 60.0% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 1 week running (as of 20 November 2026). ### Will NGL Fine Chem's share price go up? This page does not forecast NGL Fine Chem Ltd's share price. What it shows instead: the share price is ₹2,747.60, and it has been rising for 41 weeks. Its P/E of 26.6× is higher than 36% of its own last 11 years (as of 20 November 2026). ### Who owns NGL Fine Chem? Promoters own 72.5% of NGL Fine Chem Ltd, foreign institutions 0.0%, domestic institutions 0.0% and the public 27.5% (latest quarter). No group of owners changed its stake by a full point over the last two years (as of 20 November 2026). ### Does NGL Fine Chem have too much debt? NGL Fine Chem Ltd has a moderate amount of debt: its debt is 0.37× its equity, and its operating profit is 16 times its interest bill. FY26 borrowings were ₹123 Cr against equity of ₹329 Cr. Keep that borrowing in mind when reading the returns on this page (as of 20 November 2026). ### Where is NGL Fine Chem in its business cycle? NGL Fine Chem Ltd's FY26 operating margin was 16.0%, against a 13-year range of 9.5% to 31.0%. The latest quarter was 17.6%, the middle of its own range, neither a peak nor a low. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 20 November 2026). ### What could break the NGL Fine Chem story? Biggest thing to watch: the price has already been rising for 41 weeks, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 20 November 2026). ### Is NGL Fine Chem a stock worth studying right now? What the numbers show: NGL Fine Chem Ltd's earnings have grown faster than its share price. Earnings per share grew +127.9% in a year while the price moved +105.8%. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 20 November 2026). ### Is there a NGL Fine Chem share price forecast for 2026? What management itself guided: Phase II utilization 30-40% over next 2-3 quarters with room for both regulated and existing demand for next 3 years. ### Where does this page get NGL Fine Chem's management information? From NGL Fine Chem's results calls, its filings and public records on governance, each dated on the page. Management’s plans are shown as plans, never as results. ## Lists - Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india This is research, not advice. We’re not SEBI-registered.